(Q45935554)

18 December 2017

title

Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis. (English)

1 reference

18 December 2017

1

Jonathan Corren

1 reference

18 December 2017

author name string

David Diaz-Sanchez

2

1 reference

18 December 2017

Andrew Saxon

3

1 reference

18 December 2017

Yamo Deniz

4

1 reference

18 December 2017

James Reimann

5

1 reference

18 December 2017

Don Sinclair

6

1 reference

18 December 2017

Teresa Davancaze

7

1 reference

18 December 2017

Daniel Adelman

8

1 reference

18 December 2017

publication date

1 September 2004

1 reference

18 December 2017

Annals of Allergy, Asthma & Immunology

published in

1 reference

18 December 2017

volume

93

1 reference

18 December 2017

issue

3

1 reference

18 December 2017

page(s)

243-248

1 reference

18 December 2017

Molecular basis of allergic diseases

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961495-0

7 January 2021

Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961495-0

7 January 2021

The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961495-0

7 January 2021

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961495-0

7 January 2021

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961495-0

7 January 2021

Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961495-0

7 January 2021

Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961495-0

7 January 2021

Tryptase levels in nasal-lavage fluid as an indicator of the immediate allergic response

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961495-0

7 January 2021

Diesel exhaust particles induce local IgE production in vivo and alter the pattern of IgE messenger RNA isoforms

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961495-0

7 January 2021

Diesel exhaust particles directly induce activated mast cells to degranulate and increase histamine levels and symptom severity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961495-0

7 January 2021

Two unusual forms of human immunoglobulin E encoded by alternative RNA splicing of epsilon heavy chain membrane exons

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961495-0

7 January 2021

Anti-IgE efficacy in murine asthma models is dependent on the method of allergen sensitization

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961495-0

7 January 2021

Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961495-0

7 January 2021

Fluticasone propionate aqueous nasal spray reduces inflammatory cells in unchallenged allergic nasal mucosa: effects of single allergen challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961495-0

7 January 2021

10.1016/S1081-1206(10)61495-0

Identifiers

DOI

1 reference

18 December 2017

PubMed ID

15478383

1 reference

18 December 2017